Welcome to the PharmCast Research Store. Gain access to market leading research in your industry. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (29)

5,000 - 9,999 (56)

10,000 - 49,999 (113)

50,000+ (40)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (20)

500 - 999 (11)

1,000 - 1,999 (45)

2,000+ (189)

Top stories

Biogen Idec reports higher Q3 net income, provides annual outlook

Biogen Idec Inc., a biotechnology company, has reported that net income attributable to the company for the third quarter ended September 30, 2014 was $856.86 million, or $3.62 per diluted share, compared to $487.62 million, or $2.05 per diluted share, for the same quarter ended September 30, 2013. For 2014, the company expects GAAP diluted EPS to be between $12.00 and $12.10, and non-GAAP diluted EPS to be between $13.45 and $13.55...more >>

Invacare reports net loss for Q3

Invacare Corporation, a manufacturer of medical equipment, has reported that net loss for the third quarter ended September 30, 2014 were $15.1 million, or $0.47 loss per share, compared to net earnings of $16.1 million, or $0.50 per share, for the same quarter ended September 30, 2013...more >>

BioMarin Pharmaceutical reports net income for Q3, updates Q4 guidance

BioMarin Pharmaceutical Inc. has reported that net income for the third quarter ended September 30, 2014 was $7.44 million, or $0.05 per share, compared to a net loss of $53.02 million, or $0.38 loss per share, for the same quarter ended September 30, 2013. For fourth quarter of 2014, the company expects total revenues to be in the range of $700 to $710 million, compared to the prior guidance of $680 to $700...more >>

Merck receives breakthrough therapy designation from FDA for lung cancer drug

Merck & Co., Inc. has received breakthrough therapy designation from the FDA for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with epidermal growth factor receptor, or EGFR, mutation-negative, and anaplastic lymphoma kinase, or ALK, rearrangement-negative non-small cell lung cancer, or NSCLC, whose disease has progressed on or following platinum-based chemotherapy...more >>

More headlines

Ipsen and Lexicon sign licensing agreement for carcinoid syndrome treatment
Published 29 October 2014 - MarketLine

AirStrip and IBM partner to develop new mobile monitoring solution
Published 29 October 2014 - MarketLine

Allscripts partners with ScriptSave for new prescription savings program
Published 29 October 2014 - MarketLine

Epizyme announces resignation of chief medical officer
Published 29 October 2014 - MarketLine

PerkinElmer launches imaging system for cancer immunology research
Published 29 October 2014 - MarketLine

Vermillion appoints COO
Published 29 October 2014 - MarketLine

Edwards Lifesciences reports higher Q3 net income, provides Q4 outlook
Published 29 October 2014 - MarketLine

ChenMed deploys 8x8 Virtual Office services
Published 29 October 2014 - MarketLine

Varian Medical Systems Q4 net earnings down
Published 29 October 2014 - MarketLine

Align Technology reports higher Q3 net profit, provides Q4 guidance
Published 29 October 2014 - MarketLine

HCA names board chairman
Published 29 October 2014 - MarketLine

Browse all news >>